Context: Currently, no recurrence or mortality risk systems consider molecular testing when predicting thyroid cancer outcomes.
cancer types (4) , including thyroid cancer (5) . The prognostic power of mutations in the TERT promoter highlights their potential use as a clinical biomarker in thyroid cancer (6, 7) and other cancers with low rates of self-renewal, such as cancers of the brain, liver, and melanocytes (8) . Furthermore, a new robust molecular classification of glioma subtype has been proposed, based on three common genetic alterations including the TERT promoter mutation (9) . However, currently, no recurrence or mortality risk systems consider molecular testing results when predicting thyroid cancer outcomes.
In 2015, the American Thyroid Association announced new treatment guidelines for differentiated thyroid cancer (DTC) that highlight the reclassification of cancer recurrence risk after initial treatment. These guidelines have been very useful in applying a composite of information that is available in daily practice at thyroid cancer clinics (10) (11) (12) . This dynamic risk stratification (DRS) system predicts structural recurrence with higher accuracy than traditional classification based on clinical and pathologic information at baseline (13) (14) (15) .
Herein, the authors aimed to refine risk prediction for structural recurrence and subsequent thyroid cancerspecific mortality using the TERT promoter mutation, in addition to the recently proposed DRS system, in a large cohort of initially nonmetastatic DTC patients with longterm follow-up at a tertiary referral center.
Patients and Methods

Study population and tissue samples
After institutional research ethics board approval, the authors retrospectively analyzed the medical records of DTC patients without distant metastasis at initial diagnosis (M0) who were treated with total thyroidectomy and therapeutic neck dissection from 1994 to 2004. In total, 404 medical records of DTC patients were abstracted for the study. Among them, 47 cases were omitted because of receiving lobectomy alone (n = 6), initial distant metastasis (n = 24), loss to follow-up (n = 6), and failure of TERT promoter sequencing (n = 11). The further analyzed cohort consisted of samples from 357 patients. In accordance with international guidelines available at the time, postoperative treatments included thyroid hormone to suppress thyroid-stimulating hormone (TSH) concentration and/or radioactive iodine treatment.
Genomic DNA was extracted using a Qiagen DNA formalin-fixed, paraffin-embedded tissue kit (Qiagen, Hilden, Germany) according to manufacturer instructions for all available tissue blocks. Promoter mutations in the TERT gene were ascertained by seminested polymerase chain reaction and sequencing as previously described (2, 7, 16) . Clinical information including disease description, treatment, and outcomes were obtained from our institutional thyroid cancer database, which is maintained regularly, with each patient followed-up at least once yearly. All patients were initially staged according to the American Joint Committee on Cancer (AJCC) tumor/node/metastasis (TNM) classification system (seventh edition) that incorporates both anatomic (primary site, reginal lymph nodes, and distant metastatic sites) and nonanatomic (age at diagnosis) prognostic factors (17) .
Follow-up and outcomes
Follow-up was maintained by a database coordinator through review of clinical charts. Patient survival status and cause of death were ascertained by linkage to national death certificate data from the Korea National Statistical Office to further enhance data quality. Thyroid cancer-specific survival (CSS) was determined from time of initial surgery to last follow-up or time of death from thyroid cancer (patient death from other causes were censored at time of death). Structural recurrence, as opposed to biochemical recurrence, was defined as recurrent or persistent disease determined pathologically or cytologically to be malignant tissue and/or highly suspicious metastatic lesions on imaging studies (11, 15) . Recurrence-free survival was defined as the time from initial surgery to development of the first evidence of structural recurrence.
Dynamic risk stratification
As recommended by the 2015 American Thyroid Association guidelines (10, 11) , the authors evaluated clinical data obtained during follow-up and divided patients into four categories according to response to therapy at 1 year (6 to 18 months) after initial radioactive iodine treatment: (1) excellent response was defined as imaging negative for disease recurrence with serum thyroglobulin (Tg) ,0.2 ng/mL basal or ,1 ng/mL TSH stimulated; (2) indeterminate response was defined as nonspecific findings on imaging studies, serum Tg 0.2 to 1 ng/mL basal or 1 to 10 ng/mL TSH stimulated, or Tg antibodies stable or decreasing; (3) biochemical incomplete response was defined as imaging negative for disease recurrence with serum Tg .1 ng/mL basal or .10 ng/mL TSH stimulated or increasing Tg antibody titer; and (4) structural incomplete response was defined as structural (neck ultrasound, computed tomography) or functional (whole-body scan or 18 F-fluorodeoxyglucose positron emission tomography) evidence of disease in imaging studies with any Tg concentration.
For subsets of patients who did not undergo radioactive iodine treatment, the response was categorized according to the recently validated response definitions with modified Tg thresholds 1 year after initial surgery (18) .
Statistical analysis
The authors stratified patients with DTC by TERT promoter mutational status and categories of DRS. To derive alternative prognostic groupings, Cox regression was used to calculate unadjusted and adjusted hazard ratios (AHRs; adjusted with age at diagnosis, sex, histologic type, multifocality, tumor size, extrathyroidal invasion, lymph node metastasis, and radioactive iodine treatment) for risk of structural recurrence with TERT status and DRS combinations considering minimal hazard difference, the order of DRS categories, and the sample size balance between the prognostic groups (19) . The derived groups were termed AHR groups. Recurrence-free survival was calculated by the Kaplan-Meier method using log-rank tests for comparisons.
To estimate how well a risk stratification system explained the outcome of interest, we computed the proportions of variance explained (PVEs) in Cox regression models (11, 20, 21) . PVE (%) ranges from 0 to 100; larger numbers suggest better predictability. PVE was determined using the mathematical formula: PVE = 1 -exp (-G 2 /n), where G 2 is the maximum likelihood ratio that is determined on analysis of x 2 test associated with the null hypothesis; n is the total number of valid cases in the study (22) . In addition, we estimated the discriminating ability of the different models using the C-statistics for a model containing DRS or the AHR groups as the sole independent variable. The null value for the C-statistic was 0.5, with a maximum of 1.0 (with higher values being better) (23) . The model diagnostic included both graphical and statistical checks of the proportional hazards assumption based on the log-minus-log plot and x 2 tests (24).
The proposed AHR grouping was evaluated via the internal validation based on 1000 datasets generated by the stratified bootstrapping technique. To avoid severe rare event problems in the bootstrap datasets, we broke the original dataset into subdatasets according to recurrence (yes/no) and AHR group combinations, drew a random sample with replacement respectively from each subdataset, and formed a bootstrap dataset by combing the random samples from subdatasets (25) . To check reproducibility, explanatory power, and predictability of AHR grouping, Cox regressions for structural recurrence and thyroid cancer-related death were conducted with each of 1000 bootstrap datasets, and the distributions of HR estimates, PVE values, and C-statistics were investigated.
Finally, the authors calculated thyroid CSS for each AHR group. The performance of the AHR grouping was assessed against the seventh edition AJCC TNM system for predicting thyroid CSS. Statistical analysis was performed using SAS 9.4 (SAS Institute, Cary, NC) and R 3.3.2 (The R Foundation, Vienna, Austria; http://www.R-project.org/) software. All tests were two-sided with P , 0.05 considered statistically significant. Table 1 shows the characteristics of the 357 patients with DTC at baseline. The vast majority of tumors were unifocal (72.3%) and papillary thyroid cancer (85.7%). In 42.3% of patients, age at diagnosis was over 45 years; in 63.3% of patients, AJCC TNM classification was stage I or II. TERT promoter mutations were detected in 8.4% of patients: 7.6% were TERT C228T and 0.8% were C250T mutations. According to the DRS system, patients were classified into four prognostic groups according to the response to initial therapy: excellent (35.0%), indeterminate (46.8%), biochemical incomplete (8.7%), and structural incomplete (9.5%).
Results
There were 90 structural recurrences (25.2%) over a median follow-up of 14 years (range, 1 to 21 years). A reduction in 10-year recurrence-free survival (RFS) in higher DRS groups was evident [92.7%, 81.3%, 43.9%, and 41.2% for excellent, indeterminate, biochemical incomplete, and structural incomplete responses, respectively; P , 0.001; Fig. 1(b) ]. When patients were stratified according TERT promoter mutational status, the HRs for structural recurrence increased with increasing DRS severity both in mutant and wild-type (WT) TERT (P for trend ,.001 and 0.026; Table 2 ).
AHR modeling produced the following four prognostic groups (Tables 3 and 4) : AHR 1 (patients with excellent response and WT TERT), AHR 2 (patients with indeterminate response and WT TERT), AHR 3 (patients with biochemical/structural incomplete response and WT TERT or with excellent/indeterminate response and mutant TERT), AHR 4 (patients with biochemical/ structural incomplete response and mutant TERT), with corresponding 10-year RFS rates of 94.9%, 82.7%, 50.2%, and 23.1%, respectively (P , 0.001). Table 4 shows AHR grouping as a predictor of structural recurrence after adjusting for coexisting conditions. The Kaplan-Meier analysis of RFS [ Fig. 1(a)] showed that each increase in AHR severity was associated with increased structural recurrence (P , 0.001). The calculated hazard ratios were placed within the interquartile ranges of hazard ratio distribution produced from 1000 bootstrap datasets (Supplemental Fig. 1 ) and were also contained in the 95% bootstrap confidence intervals (CIs). The PVEs indicating the ability of AHR and DRS grouping to explain the risk of recurrence were 22.4% (95% CI, 20.2 to 24.6) and 18.5% (95% CI, 14.4 to 22.7), respectively [ Fig. 1(a) and 1(b) ]. The C-statistics indicating risk predictability were 0.75 (95% CI, 0.74 to 0.76) for AHR and 0.73 (95% CI, 0.70 to 0.76) for DRS alone. Of note, patterns of initial recurrence showed that distant recurrence, as opposed to locoregional recurrences, seemed to be more common in patients with higher AHR groups than those with lower AHR groups (17.6% in AHRs 3 and 4 vs 5.1% in AHRs 1 and 2, P = 0.07) when the analysis was performed separately using only the recurrent cases. There were 17 deaths (4.8%) during follow-up, and the majority of patients (88.2%) died of thyroid cancer. The survivors ranked the lower AHR groups (79.5% were AHRs 1 and 2) than those who died of thyroid cancer (80.0% were AHR 3s and 4, P , 0.001). Table 5 and Fig. 1(c) show that AHR group was also a predictor of death from thyroid cancer after correction for coexisting conditions. Whereas there was no thyroid cancer-related death among the AHR 1 group, the highest AHR group (AHR 4) was associated with a mortality rate of 23.1% at 10 years. These same data are shown in Fig. 1(d) in relation to the AJCC TNM stage. The PVEs for the risk of thyroid cancer-specific death were 11.5% (95% CI, 11.0 to 12.1) for the AHR grouping and 7.4% (95% CI, 2.7 to 12.1) for the AJCC TNM system [ Fig. 1(c) and 1(d) ]. The C-statistic values were 0.86 (95% CI, 0.85 to 0.87) for AHR and 0.80 (95% CI, 0.69 to 0.91) for AJCC TNM system.
Discussion
A considerable body of evidence supports the hypothesis that cancers with TERT mutated DTC and WT DTC show different clinical behaviors and may require different treatment choices (26, 27) . However, there is currently a lack of consensus about how best to incorporate specific molecular markers into prognostication of thyroid cancer in the context of other clinicopathologic risk factors. Refined prognostic groups of nonmetastatic DTC assume routine assessment of TERT promoter mutational status, because the plausibility or practicality of considering all nonmetastatic DTC genotypic variants of the same disease with identical DRS classification is questionable. The overall poor prognosis of patients with TERT mutated thyroid cancer even after successful initial treatment represents a legacy effect of the mutations and suggests that molecular subtyping based on TERT status will be useful in improving management of individual patients.
To our knowledge, this is the first work to demonstrate an improvement in risk stratification for oncologic outcomes by using TERT status in conjunction with the 2015 American Thyroid Association DRS system, which is a widely applicable risk stratification paradigm for structural recurrence. Our overarching hypothesis that the risk prediction based on standard clinicopathologic risk factors can be augmented by molecular findings is further supported by the important observation by Dr. Xing et al. that reported significant interactions between BRAF V600E mutation and several established risk factors, such that the risk of mortality was higher in patients with the mutation compared with those with WT in the setting of lymph node metastasis, distant metastasis, AJCC TNM stage IV, and age $45 years at diagnosis (28). For predicting disease mortality, AJCC TNM staging is recommended for all patients with DTC. However, the system imperfectly predicts thyroid cancer-specific deaths in individual patients because it does not take into account important clinicopathologic features such as tumor histology, molecular profile, or effectiveness of initial therapy (11) . Although the refined AHR groups were proposed to optimize prediction of structural recurrence after initial therapy, a surrogate outcome (29) , it also satisfies the prognostic needs of the nonmetastatic DTC population by serving as a tool to determine survival prediction. The authors believe that the AHR grouping is useful because it includes one domain that quantifies the early treatment response (DRS) and another domain that is an independent predictor of thyroid cancer-specific death (TERT mutations) (7) .
It has been noted in a previous study that there was residual risk of recurrence (14% during a median of 7 years of follow-up) among initially high-risk patients who showed excellent response and therefore may require more intense follow-up (15) . As TERT mutations are often associated with aggressive histologic features, the previous results corroborate our finding that TERT mutated cases should be regarded as AHR 3, even though they achieved short-term remission. However, the mortality risk among patients in this category was quite low compared with the morality risk of patients in the AHR 4 group, who showed persistent biochemical or structural evidence of disease after initial therapy. Therefore, from the standpoint of thyroid cancerrelated death, it is important for patients with TERT mutated DTC to achieve at least an indeterminate response after 1 year of initial therapy (Supplemental Table 1 ).
For AHR 4 patients, it is questionable whether additional adjuvant radioiodine ablation can reduce later loco-regional and distant recurrence. The TERT mutations are closely related with stemness of the cancer cells (30) and dedifferentiated histology (7) , which indicate poor response to radioiodine ablation therapy. A recent Chinese study in patients with metastatic DTC reported that those with TERT mutated tumors showed less radioiodine uptake, as demonstrated by lower mean tumor/background ratios in posttherapeutic scan images, than those with WT TERT tumors (31) . Thus, the authors suggest that AHR 4 be prespecified as a radioactive iodine refractory DTC (32) and be considered first for redifferentiation therapy (12, 33) , such as mitogen-activated protein kinase kinase inhibitor (selumetinib) (34) or selective BRAF inhibitor (dabrafenib) (35) enhanced radioactive iodine uptake, rather than unconditional repeat administration of radioisotope.
There are several limitations to this study. First, this was a retrospective study and was thus prone to selection bias. Second, the proposed AHR groupings were derived from the data set of a single institution that might not be generalizable to the population at large. Therefore, external validation is encouraged using independent comprehensive data sets that comprise the full spectrum from early to advanced disease, which are often unavailable in prospective data sets. Third, many of the CIs were very wide in the multivariate analyses which indicated poor power or precision, because of the small sample size of these subgroups. Lastly, we did not address the classification in metastatic (M1) disease given the high likelihood of persistent structural disease in this population.
In summary, the AHR grouping, a simple twodimensional prognostic system, is as effective as DRS at predicting structural recurrence and provides clinical implication for long-term CSS in patients with nonmetastatic DTC.
The present data also demonstrate that the DRS template can be used to incorporate molecular markers into the classification while also permitting follow-up information to be updated. Novel therapeutic options are needed to target patients in the AHR 4 group. 
